Ascletis Pharmaceuticals Co., Ltd. clinical trials

A subsidiary of Ascletis Pharma Inc.

The registry lists 25 studies whose lead sponsor is Ascletis Pharmaceuticals Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 18, 2025.

Studies

Recruiting first, then most recently updated. Showing 25 of 25. All Ascletis Pharma Inc. studies →

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid TumorsCompletedNCT05287399Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisCompletedNCT06248008Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisCompletedNCT06192264Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne VulgarisCompletedNCT05104125Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsCompletedNCT04465890Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIVCompletedNCT05330143Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy SubjectsCompletedNCT05718518Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 PatientsWithdrawnNCT05596045Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBMActive, not recruitingNCT05118776Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBVCompletedNCT05107778Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy SubjectsCompletedNCT05523141Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy SubjectsCompletedNCT04965337Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy SubjectsCompletedNCT04843449Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Relative Bioavailability of ASC41 in Healthy SubjectsCompletedNCT04527250Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Pharmacokinetics of ASC09F in Healthy SubjectsCompletedNCT04547894Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedNCT04358523Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedNCT03020095Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedNCT03362814Phase 2/3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy SubjectsCompletedNCT04352361Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedNCT03020004Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03430830Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03020134Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03288636Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03019991Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.